Background: Alzheimer’s disease is increasingly recognized as a disorder with metabolic and inflammatory components linked to insulin resistance and impaired glucose metabolism. Incretin-based therapies, particularly GLP-1 receptor agonists, have emerged as potential disease-modifying candidates due to their neuroprotective and metabolic actions. Aims: To provide a comprehensive and critical synthesis of current evidence on incretin-based therapies with a focus on semaglutide in Alzheimer’s disease, integrating mechanistic, preclinical, and clinical findings, and to identify key research gaps and priorities for future studies. Methods: A narrative evidence-based review was conducted in accordance with PRISMA principles. Literature was searched in PubMed and Google Scholar for English-language publications from February 2023 to June 2025 using the keywords “Alzheimer’s disease,” “semaglutide,” and “GLP-1 receptor agonists.” A total of 439 records were identified; 40 publications were analyzed, and 16 studies met the inclusion criteria for qualitative synthesis (7 preclinical, 5 clinical, and 4 reviews). Results: In preclinical models, semaglutide improved cognition, reduced neuroinflammation and oxidative stress, and attenuated β-amyloid and tau pathology. Early clinical and observational studies indicate potential neuroprotective effects and an acceptable safety profile, although data remain heterogeneous and underpowered. Evidence concerning blood–brain barrier (BBB) penetration, dose - response dynamics, and comparative efficacy versus other GLP-1RAs is still incomplete. Conclusions: Semaglutide represents a biologically plausible and clinically promising candidate for disease modification in Alzheimer’s disease. Confirmation requires long-term, placebo-controlled clinical trials with standardized cognitive and biomarker endpoints, predefined patient stratification by metabolic status and APOE4 genotype, exploration of alternative administration routes, and identification of predictors of therapeutic response.